To address the protein expression of COL3A1 in colon cancers, we performed an IHC analysis of COL3A1 expression using a commercially available TMA containing 90 cases of colorectal adenocarcinoma, which 46 cases were completed and 44 were censored (Supplementary Table 1). This evidence concerns the gene COL3A1 and colorectal adenocarcinoma.